Editas Medicine Receives Approval for EDIT-401 Gene-Editing Clinical Trial

Key Facts

1Editas Medicine received approval in Australia to initiate the Phase 1/2 Strive clinical trial of EDIT-401 for Heterozygous Familial Hypercholesterolemia.

2The company plans to begin patient dosing this year and report initial safety and tolerability data in Q1 2027.

Editas Medicine received regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial of EDIT-401 for the treatment of Heterozygous Familial Hypercholesterolemia. GlobeNewswire reported that the company plans to begin patient dosing this year and expects to report initial safety and tolerability data in the first quarter of 2027.

EDIT closed at $2.75 on October 7, 2026, after reaching a session high of $2.85 and a low of $2.66. The trial aims to provide a gene-editing solution for patients requiring additional LDL-C lowering, with the company targeting the completion of enrollment for the dose-finding portion of the study and the release of topline efficacy results later in 2027.